JPMorgan Chase & Co. Has $79.08 Million Stake in Illumina, Inc. $ILMN

JPMorgan Chase & Co. raised its position in Illumina, Inc. (NASDAQ:ILMN) by 17.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 832,690 shares of the life sciences company’s stock after buying an additional 124,246 shares during the quarter. JPMorgan Chase & Co.’s holdings in Illumina were worth $79,081,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Generali Asset Management SPA SGR boosted its position in shares of Illumina by 51.6% during the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after acquiring an additional 7,574 shares in the last quarter. Aaron Wealth Advisors LLC raised its position in Illumina by 342.6% during the third quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock valued at $995,000 after purchasing an additional 8,109 shares in the last quarter. Elo Mutual Pension Insurance Co acquired a new position in Illumina during the third quarter valued at approximately $2,319,000. Douglas Lane & Associates LLC lifted its stake in Illumina by 6.6% during the third quarter. Douglas Lane & Associates LLC now owns 307,609 shares of the life sciences company’s stock worth $29,214,000 after purchasing an additional 18,914 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in Illumina by 148.6% during the third quarter. Nordea Investment Management AB now owns 32,657 shares of the life sciences company’s stock worth $3,024,000 after purchasing an additional 19,519 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Up 1.7%

Shares of NASDAQ:ILMN opened at $122.95 on Thursday. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $155.53. The company has a market capitalization of $18.80 billion, a PE ratio of 22.56, a price-to-earnings-growth ratio of 2.31 and a beta of 1.45. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The company has a fifty day moving average of $131.64 and a 200-day moving average of $120.41.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.09. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.During the same quarter last year, the business posted $0.95 EPS. Illumina’s revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Activity at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 2.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ILMN. Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. JPMorgan Chase & Co. reduced their price objective on Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. UBS Group reiterated a “neutral” rating and issued a $135.00 target price on shares of Illumina in a research report on Friday, February 6th. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Finally, TD Cowen reissued a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Six research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $129.69.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.